Primary sclerosing cholangitis

Albireo to Report Q3 2022 Financial Results on November 8, 2022

Retrieved on: 
Monday, October 31, 2022
Itch, Institute of Liver and Biliary Sciences, Event, OLE, Primary sclerosing cholangitis, Webcast, Adult, Investor, Company, GLOBE, Alagille syndrome, IND, PFIC, Liver disease, Biliary atresia, Review, AstraZeneca, Nasdaq, Wales, Pharmaceutical industry

ET onNovember 8, 2022, to provide a business update and review the companys financial results for the quarter endedSeptember 30, 2022.

Key Points: 
  • ET onNovember 8, 2022, to provide a business update and review the companys financial results for the quarter endedSeptember 30, 2022.
  • To access the live conference call by phone, dial 1-855-327-6837(domestic) or 1-631-891-4304 (international), and provide the access code 10020423.
  • Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases.
  • Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.

LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022

Retrieved on: 
Friday, October 28, 2022
MBBS, Therapy, Seminal vesicles, Company, Hubli railway division, Institute of Liver and Biliary Sciences, AASLD, Fibrosis, Safety, Disease, Internal medicine, Liver disease, Inflammation, Hepatology, PSC, Department, Neurodegeneration, LMT, Division, Program, Patient, Association, Technology, American Association for the Study of Liver Diseases, Cirrhosis, Degenerative disease, American Association, Research, Mayo Clinic, Liver, Steatosis, NASH, Exosome, EVS, Population, Lists of diseases, Primary sclerosing cholangitis, Time, Dietary supplement, Pharmaceutical industry, Gastroenterology

SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today announced that a new drug candidate for NASH was selected for an oral presentation at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2022, to be held November 4-8 in Washington DC. As part of the presentation, LISCure will become the first Korean biotech company accepted for an oral presentation at AASLD The Liver Meeting.

Key Points: 
  • As part of the presentation, LISCure will become the first Korean biotech company accepted for an oral presentation at AASLD The Liver Meeting.
  • Oral Presentation Date and Time: Monday, November 7, 2022, 4:30 PM
    AASLD is the leading global association in the liver disease field founded in 1950.
  • AASLD The Liver Meeting is an annual event in which more than 10,000 attendees - hepatologists, health professionals, and pharmaceutical industry - participate from around the world.
  • LISCure's new drug, a clinical-stage novel strain candidate, aims the "first-in-class" microbiome-based therapy for NASH and other liver diseases.

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

Retrieved on: 
Friday, October 28, 2022
Therapy, Abstract, Fibrosis, Doctor of Philosophy, Entrepreneurship, Inflammation, CCL24, CMMB, Cirrhosis, TEL, Primary sclerosing cholangitis, Pharmaceutical industry, Management

TEL AVIV, Israel, Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .

Key Points: 
  • TEL AVIV, Israel, Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd .
  • (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November.
  • Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.
  • CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update

Retrieved on: 
Thursday, October 27, 2022
U.S. Securities and Exchange Commission, Primary sclerosing cholangitis, DHODH, Private Securities Litigation Reform Act, Metabolism, Nature, Annual report, NEW, Degenerative disease, COVID-19, Clinical trial, Drug development, SEC, Risk, Security (finance), Psoriasis, Multiple sclerosis, Vaccine, Webcast, Short course immune induction therapy

NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2022, including a corporate update, on Thursday, November 3, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

Key Points: 
  • To participate in the webcast, please register in advance at: https://imux.zoom.us/webinar/register/WN_g6raQxUTRQuuryWUU4Umig or on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations .
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at: ir.imux.com/events-and-presentations .
  • IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Think tank’ develops proposals to leverage precision medicine to improve cholangiocarcinoma patient outcomes

Retrieved on: 
Tuesday, October 25, 2022
Quality of life, Method, Lung, Caregiver, Cholangiocarcinoma, Stent, Sidney Kimmel, Disease, Therapy, Bile duct, Neoplasm, Bile, Diagnosis, Science, List of American Medical Association journals, Education, JAMA Network Open, Foundation, Patient, Biology, Primary sclerosing cholangitis, Research, Colonoscopy, Sidney Kimmel Comprehensive Cancer Center, Precision medicine, Cancer, Gallbladder, Roy Taylor (scientist), Incidence, Awareness, Liver, Survival, GLOBE, Smoker, CCA, PSC, CCF, Cohort study, Leadership, Medical device, Medical imaging, Pharmaceutical industry, Vaccine

This effort, made possible by generous philanthropic donations to the Cholangiocarcinoma Foundation , was the first of its kind in the cholangiocarcinoma (CCA) field.

Key Points: 
  • This effort, made possible by generous philanthropic donations to the Cholangiocarcinoma Foundation , was the first of its kind in the cholangiocarcinoma (CCA) field.
  • The primary themes precision prevention, early detection, and precision therapeutics reflected areas of urgency and opportunity for improving outcomes for people impacted by CCA.
  • Cholangiocarcinoma is a type of cancer that forms in the slender tubes called bile ducts that carry the digestive fluid bile.
  • Its mission is to find a cure for cholangiocarcinoma (bile duct cancer) and improve the quality of life for patients.

HighTide Therapeutics Announces Presentations at The Liver Meeting® 2022

Retrieved on: 
Tuesday, October 25, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Dysbiosis, Risk, Therapy, Non-alcoholic fatty liver disease, T2DM, American Association for the Study of Liver Diseases, Population, Gut microbiota, Cholestasis, Alkaline phosphatase, Lists of diseases, Liver injury, Primary sclerosing cholangitis, HIV disease progression rates, Fatty liver disease, Orphan drug, NASH, Liver, AASLD, HighTide, American Association, Association, 2021 Essex County Council election, Fast Track, ALP, PSC, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Dietary supplement, Patient

HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).
  • Emerging evidence supports the bidirectional relationship between intestinal microbiota and liver health.
  • Dysbiosis has been associated with the pathogensis and progression of multiple metabolic diseases and chronic inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
  • Presentations at the Liver Meeting 2022 include:
    We are very pleased to share these data, said Liping Liu, Ph.D., founder and Chief Executive Officer of HighTide.

EQS-News: Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Retrieved on: 
Saturday, October 22, 2022
Psoriasis, U.S. Securities and Exchange Commission, SEC, Multiple sclerosis, Cytokine, Degenerative disease, Part, Antibody, Patient, Drug development, Primary sclerosing cholangitis, Security (finance), Nasdaq, Private Securities Litigation Reform Act, NEW, Serum, Psoriasis Area and Severity Index, PBMC, DHODH, Graft-versus-host disease, Nature, Safety, Clinical trial, Public expenditure, Inflammatory bowel disease, Metabolism, COVID-19, Human, Pharmaceutical industry, Vaccine, T helper 17 cell, Short course immune induction therapy

The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index (PASI) reductions in the two active arms did not separate from placebo at four weeks.

Key Points: 
  • The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index (PASI) reductions in the two active arms did not separate from placebo at four weeks.
  • The primary objective was the evaluation of the safety and tolerability of IMU-935 in moderate-to-severe psoriasis patients.
  • The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period.
  • The unexpected high placebo rates observed in this interim analysis are disappointing and confound the evaluation of activity in the investigated active treatment arms.

HighTide Therapeutics Appoints Daniel Ripley as SVP Business Development

Retrieved on: 
Thursday, October 20, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, San Diego State University, Therapy, T2DM, Business administration, Master of Business Administration, Primary sclerosing cholangitis, Business, Fatty liver disease, Orphan drug, Senior, Partnership, NASH, Ionis Pharmaceuticals, HighTide, Novartis, Apricus Biosciences, CEO, Business development, Fast Track, Conatus, Head, PSC, Solution, Greater China, Program, Pharmaceutical industry, Management, Microbiology

HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.
  • Mr. Ripley has 25 years of experience in pharmaceutical business development.
  • Prior to Alpha Biopharma, Mr. Ripley served in several senior business development roles.
  • Prior to Conatus, Mr. Ripley was Senior Director, Business Development at Apricus Biosciences and Director, Business Development at Ionis Pharmaceuticals.

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Retrieved on: 
Monday, October 17, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Colon, Therapy, Neoplasm, EMA, Hyponatremia, NASDAQ, Antibody, Lymphocytopenia, SD, University, Abdominal distension, Primary sclerosing cholangitis, Association, Pseudomyxoma peritonei, CEO, Toxic leukoencephalopathy, University of California, San Francisco, Mesothelioma, UCSF, Database administrator, Population, Data, HIV disease progression rates, Cancer, Private Securities Litigation Reform Act, TRT, Department, Literature, Peptide, FDA, Isotope, RECIST, FAP, EANM, Kidney, Research, Security (finance), Cell, Trial of the century, Gallium, U.S. Securities and Exchange Commission, Radiation, Clovis Oncology, View, Sarcoma, Patient, Radiology, Gallbladder cancer, Drug discovery, Molecular Therapy, Toxicity, Safety, Biomedicine, Pharmaceutical industry, Medical imaging, Pharmacokinetics

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).
  • The Phase 1 portion of the LuMIERE study is evaluating the safety of the investigational therapeutic agent 177Lu-FAP-2286 to identify the recommended Phase 2 dose and schedule.
  • The LuMIERE trial is the first prospective trial of a FAP peptide targeted radionuclide therapy and is currently in the dose escalation phase.
  • Updated results from the Phase 1 portion of the ongoing Phase 1/2 LuMIERE study found treatment-emergent adverse events (TEAEs) were mostly Grade 1 and 2 across cohorts.

Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

Retrieved on: 
Wednesday, October 12, 2022
Institute of Liver and Biliary Sciences, AstraZeneca, Primary sclerosing cholangitis, Webcast, Hepatitis B virus, Conference, IND, Albireo, OLE, Biliary atresia, Alagille syndrome, Nasdaq, Company, Wales, PFIC, Itch, Adult, GLOBE, HBV, Pharmaceutical industry

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on October 18, 2022.

Key Points: 
  • BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on October 18, 2022.
  • A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com .
  • Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases.
  • Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.